Literature DB >> 10415673

D3 receptors and the actions of neuroleptics in the ventral striatopallidal system of schizophrenics.

J N Joyce1, E V Gurevich.   

Abstract

The mesolimbic dopamine (DA) system and an important target receptor, the D3 receptor, have been implicated in schizophrenia. We have identified, using non-radioactive in situ hybridization histochemistry, that D3 mRNA-positive neurons are highly concentrated in the ventral striatum, efferents of the ventral striatum (globus pallidus internal, ventral palladium, substantia nigra pars reticulata), and in regions projecting to the ventral striatum (medial dorsal thalamus, nucleus basalis, extended amygdala). D3 receptors are also highly enriched in the "limbic" striatal-pallidal-thalamic loop, exhibiting segregation from the D2 receptor-enriched "motor loop." This supports data developed in rats showing that the D3 receptor is a target of the mesolimbic DA system that can modulate the limbic striatal-palladial-thalamic loop. However, D2 and D3 receptors and their mRNAs are co-localized in many sensory regions (lateral and medial geniculate nuclei, basolateral and basomedial amygdala, regions of thalamus), suggesting mechanisms of cross-talk. We have also demonstrated that there are 45% elevations in D3 receptor number in ventral striatal neurons and their striatopalladial targets in schizophrenics that is reduced by concurrent antipsychotic treatment. Chronic haloperidol treatment to rats for 6 months with a 2-month withdrawal does not result in elevated D3 receptor number. We hypothesize that antipsychotic treatment via D3 receptors returns balance to limbic efferents of the ventral striatum. We established that early neonatal damage to the nigrostriatal DA system in rats produces characteristic adaptations in the pre- and post-synaptic components of the mesolimbic DA system that can provide a model to explore regulation by antipsychotics. This includes elevated release of DA from the mesolimbic DA terminals, elevated D3 receptor mRNA in the Islands of Calleja and nucleus accumbens, and enhanced behavioral response to psychostimulants.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10415673     DOI: 10.1111/j.1749-6632.1999.tb09291.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  13 in total

Review 1.  Neuropsychiatry of the basal ganglia.

Authors:  H A Ring; J Serra-Mestres
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-01       Impact factor: 10.154

2.  Going Back to Kahlbaum's Psychomotor (and GABAergic) Origins: Is Catatonia More Than Just a Motor and Dopaminergic Syndrome?

Authors:  Dusan Hirjak; Katharina M Kubera; R Christian Wolf; Georg Northoff
Journal:  Schizophr Bull       Date:  2020-02-26       Impact factor: 9.306

3.  Effect of cyclosporin A on the uptake of D3-selective PET radiotracers in rat brain.

Authors:  Zhude Tu; Shihong Li; Jinbin Xu; Wenhua Chu; Lynne A Jones; Robert R Luedtke; Robert H Mach
Journal:  Nucl Med Biol       Date:  2011-03-03       Impact factor: 2.408

4.  Pharmacogenetics of Antipsychotic Treatment in Schizophrenia.

Authors:  Samar S M Elsheikh; Daniel J Müller; Jennie G Pouget
Journal:  Methods Mol Biol       Date:  2022

5.  Disruption of prepulse inhibition of the startle reflex by the preferential D(3) agonist ropinirole in healthy males.

Authors:  Stella G Giakoumaki; Panos Roussos; Sophia Frangou; Panos Bitsios
Journal:  Psychopharmacology (Berl)       Date:  2007-06-20       Impact factor: 4.530

6.  Basal ganglia shape abnormalities in the unaffected siblings of schizophrenia patients.

Authors:  Daniel Mamah; Michael P Harms; Lei Wang; Deanna Barch; Paul Thompson; Jaeyun Kim; Michael I Miller; John G Csernansky
Journal:  Biol Psychiatry       Date:  2008-03-04       Impact factor: 13.382

Review 7.  Integrated signaling in heterodimers and receptor mosaics of different types of GPCRs of the forebrain: relevance for schizophrenia.

Authors:  Kjell Fuxe; Daniel Marcellino; Amina S Woods; Leo Giuseppina; Tiziana Antonelli; Luca Ferraro; Sergio Tanganelli; Luigi F Agnati
Journal:  J Neural Transm (Vienna)       Date:  2009-01-21       Impact factor: 3.575

8.  Frequency of new-onset pathologic compulsive gambling or hypersexuality after drug treatment of idiopathic Parkinson disease.

Authors:  J Michael Bostwick; Kathleen A Hecksel; Susanna R Stevens; James H Bower; J Eric Ahlskog
Journal:  Mayo Clin Proc       Date:  2009-04       Impact factor: 7.616

9.  Aberrant dopamine D2-like receptor function in a rodent model of schizophrenia.

Authors:  Stephanie M Perez; Daniel J Lodge
Journal:  J Pharmacol Exp Ther       Date:  2012-08-02       Impact factor: 4.030

10.  Dynamic expression of tyrosine hydroxylase mRNA and protein in neurons of the striatum and amygdala of mice, and experimental evidence of their multiple embryonic origin.

Authors:  Munisamy Bupesh; Alba Vicario; Antonio Abellán; Ester Desfilis; Loreta Medina
Journal:  Brain Struct Funct       Date:  2013-03-12       Impact factor: 3.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.